Join the Pulmonary Hypertension group to help and get support from people like you.
Pulmonary Hypertension News
Related terms: PAH, Pulmonary Arterial Hypertension
FDA Approves Winrevair for Pulmonary Arterial Hypertension in Adults
THURSDAY, March 28, 2024 – The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults. The FDA...
FDA Approves Winrevair (sotatercept-csrk) a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE) March 26, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Opsynvi (macitentan and tadalafil) for Adults with Pulmonary Arterial Hypertension
RARITAN, NJ, March 22, 2024 – Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Opsynvi® – a single-tablet combination of macitentan, an endothelin rece...
CMP Pharma, Inc Announces that Liqrev, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available
FARMVILLE, N.C., June 21, 2023/ — CMP Pharma, Inc. announced today that Liqrev (Sildenafil) Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-made oral liquid of sildenafil, is now a...
United Therapeutics Announces FDA Approval of Tyvaso DPI
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE) May 24, 2022 – United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food...
Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
TITUSVILLE, N.J. – July 30, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Uptravi (selexipag) inj...
Actelion Receives FDA Approval of Tracleer (bosentan) for Use in Pediatric Patients with Pulmonary Arterial Hypertension
SOUTH SAN FRANCISCO, Calif, September 6, 2017 – Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug A...
FDA Approves Uptravi (selexipag) for Pulmonary Arterial Hypertension
December 22, 2015 – On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and...
FDA Medwatch Alert: Revatio (sildenafil): Drug Safety Communication - FDA Clarifies Warning About Pediatric Use for Pulmonary Arterial Hypertension
ISSUE: FDA is clarifying its previous recommendation related to prescribing Revatio (sildenafil) for children with pulmonary arterial hypertension (PAH). Revatio is FDA-approved only to treat PAH in...
FDA Approves Orenitram (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension
SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ – United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil)...
FDA Approves Opsumit to Treat Pulmonary Arterial Hypertension
October 18, 2013 – The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and...
FDA Approves Adempas to Treat Pulmonary Hypertension
October 8, 2013 – The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally...
FDA Medwatch Alert: Revatio (sildenafil): Drug Safety Communication - Recommendation Against Use in Children
ISSUE: FDA notified healthcare professionals and their medical care organizations that Revatio (sildenafil) should not be prescribed to children (ages 1 through 17) for pulmonary arterial...
FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Revatio is the Only Treatment in Its Class with Both Oral and Intravenous Formulations NEW YORK--(BUSINESS WIRE)--Nov 20, 2009 - Pfizer announced today that the U.S. Food and Drug Administration...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Cardiovascular Conditions and Disorders